WesBanco Bank’s Rigel Pharmaceuticals RIGL Stock Holding History

WesBanco Bank’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-4,000	Closed	-$134K	–	522
2013 Q2	$134K	Buy	+4,000	New	+$181K	0.01%	495

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

WesBanco Bank's RIGL Position: Q3 2013 in Review

WesBanco Bank sold out of Rigel Pharmaceuticals (RIGL) in Q3 2013, closing a stake of 4,000 shares — an estimated $134K sold.

WesBanco Bank first reported a position in RIGL in Q2 2013 and held it in 1 quarter. The position peaked at $134K in Q2 2013. 95 funds tracked by Wall St. Rank hold RIGL as of Q3 2013.

WesBanco Bank reported no remaining Rigel Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
WesBanco Bank sold 4,000 Rigel Pharmaceuticals shares in Q3 2013, an estimated $134K.
WesBanco Bank first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 1 quarter.
WesBanco Bank's Rigel Pharmaceuticals position peaked at $134K in Q2 2013.
95 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2013.

Based on WesBanco Bank's 13F filing for Q3 2013, filed 5 Nov 2013.